US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Latest News about NeuroSense Therapeutics

Recent news which mentions NeuroSense Therapeutics

NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Tickers BIIB NRSN
Tags General Partner Content Benzinga
From Benzinga
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC
Tickers NRSN
Tags NeuroSense Therapeutics NRSN Market News
From Benzinga